- Suchergebnis für K05097
Cookie-Einstellungen
Diese Website benutzt Cookies, die für den technischen Betrieb der Website erforderlich sind und stets gesetzt werden. Andere Cookies, die den Komfort bei Benutzung dieser Website erhöhen, der Direktwerbung dienen oder die Interaktion mit anderen Websites und sozialen Netzwerken vereinfachen sollen, werden nur mit Ihrer Zustimmung gesetzt.
Konfiguration
Technisch erforderlich
Diese Cookies sind für die Grundfunktionen des Shops notwendig.
"Alle Cookies ablehnen" Cookie
"Alle Cookies annehmen" Cookie
Ausgewählter Shop
CSRF-Token
Cookie-Einstellungen
FACT-Finder Tracking
Individuelle Preise
Kundenspezifisches Caching
Session
Währungswechsel
Komfortfunktionen
Diese Cookies werden genutzt um das Einkaufserlebnis noch ansprechender zu gestalten, beispielsweise für die Wiedererkennung des Besuchers.
Facebook-Seite in der rechten Blog - Sidebar anzeigen
Merkzettel
Statistik & Tracking
Endgeräteerkennung
Kauf- und Surfverhalten mit Google Tag Manager
Partnerprogramm
Zu "K05097" wurden 122 Artikel gefunden!
Filter schließen
Filtern nach:
Für die Filterung wurden keine Ergebnisse gefunden!
Artikelnummer: Cay11495-5
Receptors for VEGF have central roles in vasculogenesis and angiogenesis and thus serve as targets for cancer therapy. Cediranib is a potent inhibitor of VEGF receptor tyrosine kinases, including VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively). It also potently inhibits a variety of other receptor and...
| Schlagworte: | AZD 2171, ZD 2171, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-quinazoline |
| Anwendung: | VEGFR1/2/3 inhibitor |
| CAS | 288383-20-0 |
| MW: | 450.5 D |
ab 133,00 €
Artikelnummer: Cay12097-100
Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay). It also inhibits PDGFRalpha, PDGFRbeta, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional...
| Schlagworte: | GSK-VEG10003, GW786034B, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide |
| Anwendung: | Broad spectrum tyrosine kinase inhibitor |
| CAS | 444731-52-6 |
| MW: | 437.5 D |
ab 44,00 €
Artikelnummer: LKT-C0006.10
Cabozantinib or XL-184 is a tyrosine kinase (c-MET, VEGFR2) inhibitor. It has been shown to reduce tumor growth, metastasis, angiogenesis, and induce apoptosis.
| Schlagworte: | XL-184, BMS-907351, N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| CAS | 849217-68-1 |
| MW: | 501.51 D |
ab 128,00 €
Artikelnummer: LKT-A9435.25
VEGFR inhibitor.
| Schlagworte: | N-methyl-2-[[3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl]sulfanyl]benzamide |
| Anwendung: | PDGFRB / VEGFR1 / VEGFR2 / VEGFR3 / c-KIT tyrosine kinase inhibitor |
| CAS | 319460-85-0 |
| MW: | 386.47 D |
ab 73,00 €
Artikelnummer: Cay29425-10
Fruquintinib is a VEGFR inhibitor (IC50s = 33, 35, and 0.5 nM for VEGFR1, -2, and -3, respectively). It also inhibits RET, FGFR1, and c-Kit (IC50s = 128, 181, and 458 nM, respectively) in a panel of 253 kinases. Fruquintinib inhibits VEGF-A-induced proliferation of human umbilical vein endothelial cells (HUVECs) and...
| Schlagworte: | HMPL-013, 6-[(6,7-dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-3-benzofurancarboxamide |
| Anwendung: | VEGFR inhibitor |
| CAS | 1194506-26-7 |
| MW: | 393.4 D |
ab 75,00 €
Artikelnummer: Cay29832-500
Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively). It also inhibits the related kinases VEGFR1, FGFR1, PDGFRalpha, PDGFRbeta and KIT (IC50s = 22, 46, 51, 39, and 100 nM, respectively). Lenvatinib (30 mg/kg, twice per day) reduces...
| Schlagworte: | E-7080, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide, monomethanesulfonate |
| Anwendung: | VEGFR2 / VEGFR3 inhibitor |
| CAS | 857890-39-2 |
| MW: | 523 D |
ab 128,00 €
Artikelnummer: Cay16968-5
ZM 306416 is an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase that antagonizes the activity of KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 µM, respectively. It has also been reported to inhibit EGFR kinase with an IC50 value of 98%. Formulation: (Request formulation...
| Schlagworte: | CB-676475, N-(4-chloro-2-fluorophenyl)-6,7-dimethoxy-4-quinazolinamine |
| Anwendung: | VEGFR inhibitor |
| CAS | 690206-97-4 |
| MW: | 333.7 D |
ab 67,00 €
Artikelnummer: Cay16168-1
The VEGF receptors (VEGFRs) mediate signaling leading to angiogenesis, with VEGFR3 (FLT4), activated by VEGF isoforms VEGFC and VEGFD, primarily expressed on lymphatic endothelial cells and directing lymphangiogenesis. MAZ51 is an indolinone that selectively antagonizes the activation of VEGFR3 by VEGFC (IC50 = 1...
| Schlagworte: | 3-[[4-(dimethylamino)-1-naphthalenyl]methylene]-1,3-dihydro-2H-indol-2-one |
| Anwendung: | VEGFR-3 VEGF-C antagonist |
| CAS | 163655-37-6 |
| MW: | 314.4 D |
ab 73,00 €
Artikelnummer: AG-CR1-3623-M005
Light pink to white solid. Soluble in DMSO (>50mg/ml). Slightly soluble in ethanol (1mg/ml). Insoluble in water. Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent, Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, Kit, RET and Raf-1 with IC50 values of...
| Schlagworte: | BAY 73-4506, Fluoro-Sorafenib |
| Anwendung: | VEGFR1/2/3/PDGFRbeta/Kit/RET/Raf-1 inhibitor |
| CAS | 755037-03-7 |
| MW: | 482,8 D |
ab 39,00 €
Artikelnummer: Cay18493-1
Tivozanib is an orally available, selective VEGFR inhibitor with IC50 values of 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. It can also inhibit c-Kit and PDGFRbeta with IC50 values of 1.63 and 1.72 nM, respectively. When administered to athymic rats, tivozanib was shown to decrease the...
| Schlagworte: | AV-951, KRN 951, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-urea, monohydrate |
| Anwendung: | VEGFR inhibitor |
| CAS | 682745-40-0 |
| MW: | 472.9 D |
ab 81,00 €
Artikelnummer: Cay25486-500
Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib (Cay-18498) by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity. It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRbeta with IC50 values of 1.5, 2.5, 4.2, 7,...
| Schlagworte: | 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide |
| Anwendung: | VEGFR inhibitor, GC-MS, LC-MS, internal standard |
| CAS | 2126178-55-8 |
| MW: | 486.8 D |
ab 360,00 €
Artikelnummer: Cay27655-5
Anlotinib is an orally bioavailable tyrosine kinase inhibitor that inhibits human VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, and c-Kit (IC50s = 26.9, 0.2, 0.7, 115, and 14.8 nM, respectively). It is selective for these kinases over c-Met, c-Src, HER2, and EGFR (IC50s = >2,000 nM). It also inhibits FGFR1 (IC50 = 11.7 nM for...
| Schlagworte: | 1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]-cyclopropanamine, monohydrochloride |
| Anwendung: | Tyrosine kinase inhibitor |
| CAS | 1058157-76-8 |
| MW: | 443.9 D |
ab 54,00 €